AstraZeneca's Saphnelo received a positive recommendation from the EU Committee for Medicinal Products for Human Use (CHMP) for subcutaneous self-administration in systemic lupus erythematosus, based on interim Phase III trial results. This recommendation was made on 20 October 2025, marking a significant step towards broader access to treatment.